• 1

    SiegelRWardEBrawleyOJemalA. Cancer statistics, impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin2011;61:212-236.

    • Search Google Scholar
    • Export Citation
  • 2

    BrennerHGondosAPulteD. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood2008;111:2521-2526.

    • Search Google Scholar
    • Export Citation
  • 3

    KumarSKRajkumarSVDispenzieriA. Improved survival in multiple myeloma and the impact of novel therapies. Blood2008;111:2516-2520.

  • 4

    HideshimaTAndersonKC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer2002;2:927-937.

  • 5

    DispenzieriAKyleRMerliniG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia2009;23:215-224.

    • Search Google Scholar
    • Export Citation
  • 6

    KuhnemundALiebischPBauchmullerK. 'Light-chain escape-multiple myeloma'-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol2009;135:477-484.

    • Search Google Scholar
    • Export Citation
  • 7

    DurieBGHarousseauJLMiguelJS. International uniform response criteria for multiple myeloma. Leukemia2006;20:1467-1473.

  • 8

    KyleRAGertzMAWitzigTE. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003;78:21-33.

  • 9

    ShaughnessyJJacobsonJSawyerJ. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood2003;101:3849-3856.

    • Search Google Scholar
    • Export Citation
  • 10

    XiongWWuXStarnesS. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood2008;112:4235-4246.

    • Search Google Scholar
    • Export Citation
  • 11

    DrachJAckermannJFritzE. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood1998;92:802-809.

    • Search Google Scholar
    • Export Citation
  • 12

    Avet-LoiseauHAttalMMoreauP. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood2007;109:3489-3495.

    • Search Google Scholar
    • Export Citation
  • 13

    WiesmannUNDiDonatoSHerschkowitzNN. Effect of chloroquine on cultured fibroblasts: release of lysosomal hydrolases and inhibition of their uptake. Biochem Biophys Res Commun1975;66:1338-1343.

    • Search Google Scholar
    • Export Citation
  • 14

    GutierrezNCCastellanosMVMartinML. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia2007;21:143-150.

    • Search Google Scholar
    • Export Citation
  • 15

    Avet-LoiseauHGarandRLodeL. Translocation t(11;14) (q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood2003;101:1570-1571.

    • Search Google Scholar
    • Export Citation
  • 16

    FonsecaRBloodERueM. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood2003;101:4569-4575.

  • 17

    NairBvan RheeFShaughnessyJDJr. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood2010;115:4168-4173.

    • Search Google Scholar
    • Export Citation
  • 18

    DewaldGTherneauTLarsonD. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood2005;106:3553-3558.

    • Search Google Scholar
    • Export Citation
  • 19

    FonsecaRBarlogieBBatailleR. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res2004;64:1546-1558.

  • 20

    HanamuraIStewartJPHuangY. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood2006;108:1724-1732.

    • Search Google Scholar
    • Export Citation
  • 21

    CarrascoDRTononGHuangY. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell2006;9:313-325.

    • Search Google Scholar
    • Export Citation
  • 22

    RosinolLCarrioABladeJ. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol2005;130:729-732.

    • Search Google Scholar
    • Export Citation
  • 23

    DispenzieriARajkumarSVGertzMA. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc2007;82:323-341.

    • Search Google Scholar
    • Export Citation
  • 24

    KumarSKMikhaelJRBuadiFK. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc2009;84:1095-1110.

    • Search Google Scholar
    • Export Citation
  • 25

    MoreauPAttalMGarbanF. Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia2007;21:2020-2024.

    • Search Google Scholar
    • Export Citation
  • 26

    FonsecaRBergsagelPLDrachJ. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia2009;23:2210-2221.

    • Search Google Scholar
    • Export Citation
  • 27

    ZhouYBarlogieBShaughnessyJDJr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia2009;23:1941-1956.

    • Search Google Scholar
    • Export Citation
  • 28

    MoulopoulosLADimopoulosMAWeberD. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol1993;11:1311-1315.

    • Search Google Scholar
    • Export Citation
  • 29

    DurieBWaxmanAD'AgnoloAWilliamsCM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med2002;43:1457-1463.

  • 30

    SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361-366.

    • Search Google Scholar
    • Export Citation
  • 31

    GreippPRLustJAO'FallonWM. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993;81:3382-3387.

    • Search Google Scholar
    • Export Citation
  • 32

    The International Myeloma Working G. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol2003;121:749-757.

    • Search Google Scholar
    • Export Citation
  • 33

    GreippPRSan MiguelJDurieBGM. International staging system for multiple myeloma. J Clin Oncol2005;23:3412-3420.

  • 34

    BladeJSamsonDReeceD. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol1998;102:1115-1123.

    • Search Google Scholar
    • Export Citation
  • 35

    RajkumarSV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol2011;86:57-65.

  • 36

    KnowlingMAHarwoodARBergsagelDE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol1983;1:255-262.

    • Search Google Scholar
    • Export Citation
  • 37

    DimopoulosMAGoldsteinJFullerL. Curability of solitary bone plasmacytoma. J Clin Oncol1992;10:587-590.

  • 38

    HuKYahalomJ. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park)2000;14:101-108.

  • 39

    KatoTTsukamotoENishiokaT. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med2000;25:870-873.

    • Search Google Scholar
    • Export Citation
  • 40

    CesanaCKlersyCBarbaranoL. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol2002;20:1625-1634.

    • Search Google Scholar
    • Export Citation
  • 41

    BredellaMASteinbachLCaputoG. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol2005;184:1199-1204.

    • Search Google Scholar
    • Export Citation
  • 42.

    JadvarHContiPS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol2002;31:690-694.

  • 43

    OrchardKBarringtonSBuscombeJ. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol2002;117:133-135.

    • Search Google Scholar
    • Export Citation
  • 44

    OcqueteauMOrfaoAAlmeidaJ. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol1998;152:1655-1665.

    • Search Google Scholar
    • Export Citation
  • 45

    Perez-PersonaEVidrialesMBMateoG. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood2007;110:2586-2592.

    • Search Google Scholar
    • Export Citation
  • 46

    QuachHRitchieDStewartAK. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia2010;24:22-32.

  • 47

    Avet-LoiseauHLeleuXRousselM. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol2010;28:4630-4634.

    • Search Google Scholar
    • Export Citation
  • 48

    Chanan-KhanASonneveldPSchusterM. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:4784-4790.

    • Search Google Scholar
    • Export Citation
  • 49

    VickreyEAllenSMehtaJSinghalS. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer2009;115:229-232.

    • Search Google Scholar
    • Export Citation
  • 50

    MateosMV. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev2010;36(Suppl 2):S24-32.

  • 51

    HarousseauJLAttalMAvet-LoiseauH. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol2010;28:4621-4629.

    • Search Google Scholar
    • Export Citation
  • 52

    RichardsonPGBarlogieBBerensonJ. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med2003;348:2609-2617.

  • 53

    MateosMHernandezJHernandezM. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood2006;108:2165-2172.

    • Search Google Scholar
    • Export Citation
  • 54

    RichardsonPSonneveldPSchusterM. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med2005;352:2487-2498.

  • 55

    SonneveldPSchmidt-WolfIvan der HoltB. HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood2010;116:Abstract 40.

    • Search Google Scholar
    • Export Citation
  • 56

    CavoMTacchettiPPatriarcaF. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 158.

    • Search Google Scholar
    • Export Citation
  • 57

    CavoMTacchettiPPatriarcaF. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet2010;376:2075-2085.

    • Search Google Scholar
    • Export Citation
  • 58

    KaufmanJLNookaAVranaM. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer2010;116:3143-3151.

    • Search Google Scholar
    • Export Citation
  • 59

    RosinolLCibeiraMTMateosMV. Phase III PETHEMA/GEM study of induction therapy prior autologous stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib/thalidomide/dexamethasone) over TD and VBMCP/VBAD plus bortezomib [abstract]. Blood2010;116:Abstract 307.

    • Search Google Scholar
    • Export Citation
  • 60

    RichardsonPJagannathSRajeN. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase 1/2 study [abstract]. Blood2007;110:Abstract 187.

    • Search Google Scholar
    • Export Citation
  • 61

    RichardsonPLonialSJakubowiakA. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood2008;112:Abstract 92.

    • Search Google Scholar
    • Export Citation
  • 62

    RichardsonPWellerELonialS. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood2010;116:679-686.

    • Search Google Scholar
    • Export Citation
  • 63

    KumarSFlinnIWRichardsonPG. Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study [abstract]. Blood2010;116:Abstract 621.

    • Search Google Scholar
    • Export Citation
  • 64

    RousselMAvet-LoiseauHMoreauP. Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous stem cell transplantation, VRD consolidation and lenalidomide maintenance in newly diagnosed multiple myeloma patients: primary results of the IFM 2008 phase II study [abstract]. Blood2010;116:Abstract 624.

    • Search Google Scholar
    • Export Citation
  • 65

    RousselMFaconTMoreauP. Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. Recent Results Cancer Res2011;183:189-206.

    • Search Google Scholar
    • Export Citation
  • 66

    ReederCBReeceDEKukretiV. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia2009;23:1337-1341.

    • Search Google Scholar
    • Export Citation
  • 67

    EinseleHLiebischPLangerC. Velcade, intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) [abstract]. Blood2009;114:Abstract 131.

    • Search Google Scholar
    • Export Citation
  • 68

    KumarSFlinnIWHariPN. Novel three- and four-drug combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for newly diagnosed multiple myeloma: encouraging results from the multi-center, randomized, phase 2 EVOLUTION study [abstract]. Blood2009;114:Abstract 127.

    • Search Google Scholar
    • Export Citation
  • 69

    ZonderJACrowleyJHusseinMA. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG Trial S0232 [abstract]. Blood2007;110:Abstract 77.

    • Search Google Scholar
    • Export Citation
  • 70

    RajkumarSVJacobusSCallanderN. A randomized phase III trial of lenalidomide pus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2006;108:Abstract 799.

    • Search Google Scholar
    • Export Citation
  • 71

    RajkumarSVJacobusSCallanderN. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2007;110:Abstract 74.

    • Search Google Scholar
    • Export Citation
  • 72

    RajkumarSVJacobusSCallanderNS. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol2010;11:29-37.

    • Search Google Scholar
    • Export Citation
  • 73

    GayFHaymanSRLacyMQ. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood2010;115:1343-1350.

    • Search Google Scholar
    • Export Citation
  • 74

    KumarSDispenzieriALacyMQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:2035-2042.

    • Search Google Scholar
    • Export Citation
  • 75

    ParipatiHStewartAKCabouS. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:1282-1284.

    • Search Google Scholar
    • Export Citation
  • 76

    KumarSGiraltSStadtmauerEA. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood2009;114:1729-1735.

    • Search Google Scholar
    • Export Citation
  • 77

    ZangariMTricotGPolavaramL. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol2010;28:132-135.

    • Search Google Scholar
    • Export Citation
  • 78

    PalumboARajkumarSVDimopoulosMA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008;22:414-423.

  • 79

    RajkumarSBloodEAVesoleD. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2006;24:431-436.

    • Search Google Scholar
    • Export Citation
  • 80

    RifkinRGregorySAMohrbacherAHusseinM. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer2006;106:848-858.

    • Search Google Scholar
    • Export Citation
  • 81

    GregoryWMRichardsMAMalpasJS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol1992;10:334-342.

    • Search Google Scholar
    • Export Citation
  • 82

    PalumboABringhenSCaravitaT. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2006;367:825-831.

    • Search Google Scholar
    • Export Citation
  • 83

    FaconTMaryJYHulinC. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet2007;370:1209-1218.

    • Search Google Scholar
    • Export Citation
  • 84

    HulinCFaconTRodonP. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol2009;27:3664-3670.

    • Search Google Scholar
    • Export Citation
  • 85

    HulinCFaconTRodonP. Melphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients >=75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood2007;110:Abstract 75.

    • Search Google Scholar
    • Export Citation
  • 86

    PalumboABringhenSLiberatiAM. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood2008;112:3107-3114.

    • Search Google Scholar
    • Export Citation
  • 87

    WaageAGimsingPJuliussonG. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial [abstract]. Blood2007;110:Abstract 78.

    • Search Google Scholar
    • Export Citation
  • 88

    WijermansPSchaafsmaMvan NordenY. Melphalan + prednisone versus melphalan + prednisone + thalidomide induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON [abstract]. Haematologica2008;93:Abstract 178.

    • Search Google Scholar
    • Export Citation
  • 89

    WijermansPSchaafsmaMTermorshuizenF. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol2010;28:3160-3166.

    • Search Google Scholar
    • Export Citation
  • 90

    San MiguelJFSchlagRKhuagevaNK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med2008;359:906-917.

    • Search Google Scholar
    • Export Citation
  • 91

    MateosMVRichardsonPGSchlagR. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol2010;28:2259-2266.

    • Search Google Scholar
    • Export Citation
  • 92

    HarousseauJPalumboARichardsonP. Superior outcomes associated with complete response: analysis of the phase III VISTA study of bortezomib plus melphalan-mrednisone versus melphalan-prednisone [abstract]. Blood2008;112:Abstract 2778.

    • Search Google Scholar
    • Export Citation
  • 93

    HarousseauJLPalumboARichardsonPG. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood2010;116:3743-3750.

    • Search Google Scholar
    • Export Citation
  • 94

    YehYChambersJGaugrisSJansenJ. Indirect comparison of the efficacy of melphalan-prednisone-bortezomib relative to melphalan-prednisone-thalidomide and melphalan-prednisone for the first line treatment of multiple myeloma [abstract]. Blood2008;112:Abstract 2367.

    • Search Google Scholar
    • Export Citation
  • 95

    PalumboAFalcoPCorradiniP. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA—Italian Multiple Myeloma Network. J Clin Oncol2007;25:4459-4465.

    • Search Google Scholar
    • Export Citation
  • 96

    PalumboAFalcoPFalconeA. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma2009;9:145-150.

    • Search Google Scholar
    • Export Citation
  • 97

    RoyVStewartABergsagelP. Phase II study of melphalan, prednisone and lenalidomide combination for newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation [abstract]. Blood2008;112:Abstract 2769.

    • Search Google Scholar
    • Export Citation
  • 98

    PalumboADimopoulosMADelforgeM. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract]. Blood2009;114:Abstract 613.

    • Search Google Scholar
    • Export Citation
  • 99

    PalumboADelforgeMCatalanoJ. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients >= 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]. Blood2010;116:Abstract 622.

    • Search Google Scholar
    • Export Citation
  • 100

    NiesvizkyRFlinnIWRifkinRM. Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients [abstract]. Blood2010;116:Abstract 619.

    • Search Google Scholar
    • Export Citation
  • 101

    NiesvizkyRFlinnIWRifkinRM. Patient-reported quality of life in elderly, newly diagnosed multiple myeloma patients treated with bortezomib-based regimens: results from the phase 3b UPFRONT study [abstract]. Blood2010;116:Abstract 3026.

    • Search Google Scholar
    • Export Citation
  • 102

    BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:2574-2579.

    • Search Google Scholar
    • Export Citation
  • 103

    KrogerNSayerHGSchwerdtfegerR. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood2002;100:3919-3924.

    • Search Google Scholar
    • Export Citation
  • 104

    MoreauPFaconTAttalM. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002;99:731-735.

    • Search Google Scholar
    • Export Citation
  • 105

    SomloGSpielbergerRFrankelP. Total marrow irradiation: a new ablative regimen as part of tandem autologous stem cell transplantation for patients with multiple myeloma. Clin Cancer Res2011;17:174-182.

    • Search Google Scholar
    • Export Citation
  • 106

    AttalMHarousseauJLStoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:91-97.

    • Search Google Scholar
    • Export Citation
  • 107

    ChildJMorganGDaviesF. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:1875-1883.

  • 108

    BarlogieBKyleRAndersonK. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929-936.

    • Search Google Scholar
    • Export Citation
  • 109

    FermandJKatsahianSDivineM. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:9227-9233.

    • Search Google Scholar
    • Export Citation
  • 110

    FermandJPRavaudPChevretS. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood1998;92:3131-3136.

    • Search Google Scholar
    • Export Citation
  • 111

    HarousseauJLMathiotCAttalM. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol2008;26:Abstract 8505.

    • Search Google Scholar
    • Export Citation
  • 112

    HarousseauJAvet-LoiseauHAttalM. High complete and very good partial response rates with bortezomib—dexamethasone as induction prior to ASCT in newly diagnosed patients with high-risk myeloma: results of the IFM2005-01 phase 3 trial [abstract]. Blood2009;114:Abstract 353.

    • Search Google Scholar
    • Export Citation
  • 113

    CavoMTacchettiPPatriarcaF. A phase III study of double autotransplantation incorporating bortezomib-thalidomide-dexamethasone (VTD) or thalidomide-dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD [abstract]. Blood2009;114:Abstract 351.

    • Search Google Scholar
    • Export Citation
  • 114

    HahnTWingardJAndersonK. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant2003;9:4-37.

    • Search Google Scholar
    • Export Citation
  • 115

    KumarSLacyMQDispenzieriA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant2004;34:161-167.

    • Search Google Scholar
    • Export Citation
  • 116

    AttalMHarousseauJFaconT. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med2003;349:2495-2502.

    • Search Google Scholar
    • Export Citation
  • 117

    StadtmauerEA. Multiple myeloma, 2004—one or two transplants?N Engl J Med2003;349:2551-2553.

  • 118

    CavoMTosiPZamagniE. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol2007;25:2434-2441.

    • Search Google Scholar
    • Export Citation
  • 119

    SonneveldPvan der HoltBSegerenC. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood2004;104:Abstract 948.

    • Search Google Scholar
    • Export Citation
  • 120

    GoldschmidtH. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica2005;90(s1):Abstract 38

    • Search Google Scholar
    • Export Citation
  • 121

    BarlogieBAttalMCrowleyJ. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol2010;28:1209-1214.

    • Search Google Scholar
    • Export Citation
  • 122

    CookGLiakopoulouEPearceR. Factors influencing the outcome of a second autologous stem cell transplant (ASCT) in relapsed multiple myeloma: a study from the British Society of Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplantin press.

    • Search Google Scholar
    • Export Citation
  • 123

    OlinRLVoglDTPorterDL. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant2009;43:417-422.

    • Search Google Scholar
    • Export Citation
  • 124

    BurzynskiJAToroJJPatelRC. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma2009;50:1442-1447.

    • Search Google Scholar
    • Export Citation
  • 125

    AlvaresCLDaviesFEHortonC. The role of second autografts in the management of myeloma at first relapse. Haematologica2006;91:141-142.

  • 126

    FenkRLieseVNeubauerF. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. Leuk Lymphoma2011;52:1455-1462.

    • Search Google Scholar
    • Export Citation
  • 127

    KyleRA. High-dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol1999;26:74-83.

  • 128

    KumarALoughranTAlsinaM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol2003;4:293-304.

    • Search Google Scholar
    • Export Citation
  • 129

    BrunoBRottaMPatriarcaF. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med2007;356:1110-1120.

  • 130

    RosinolLPerez-SimonJASuredaA. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood2008;112:3591-3593.

    • Search Google Scholar
    • Export Citation
  • 131

    GarbanFAttalMMichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:3474-3480.

    • Search Google Scholar
    • Export Citation
  • 132

    StadtmauerEAKrishnanAPasquiniMC. Tandem autologous stem cell transplants (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling nonmyeloablative allogeneic stem cell transplant (auto-allo) for patients (pts) with high risk (HR) multiple myeloma (MM): results from the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 trial [abstract]. Blood2010;116:Abstract 526.

    • Search Google Scholar
    • Export Citation
  • 133

    BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:2574-2579.

    • Search Google Scholar
    • Export Citation
  • 134

    MaloneyDMolinaASahebiF. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood2003;102:3447-3454.

    • Search Google Scholar
    • Export Citation
  • 135

    CrawleyCLalancetteMSzydloR. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood2005;105:4532-4539.

    • Search Google Scholar
    • Export Citation
  • 136

    de LavalladeHEl-CheikhJFaucherC. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant2008;41:953-960.

    • Search Google Scholar
    • Export Citation
  • 137

    ZeiserRBertzHSpyridonidisA. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant2004;34:923-928.

    • Search Google Scholar
    • Export Citation
  • 138

    van de DonkNWKrogerNHegenbartU. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant2006;37:1135-1141.

    • Search Google Scholar
    • Export Citation
  • 139

    LokhorstHMWuKVerdonckLF. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood2004;103:4362-4364.

    • Search Google Scholar
    • Export Citation
  • 140

    LokhorstHMSchattenbergACornelissenJJ. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol2000;18:3031-3037.

    • Search Google Scholar
    • Export Citation
  • 141

    LokhorstHMSchattenbergACornelissenJJ. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood1997;90:4206-4211.

    • Search Google Scholar
    • Export Citation
  • 142

    SalamaMNevillTMarcellusD. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant2000;26:1179-1184.

  • 143

    TricotGVesoleDHJagannathS. Graft-versus-myeloma effect: proof of principle. Blood1996;87:1196-1198.

  • 144

    AyukFShimoniANaglerA. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia2004;18:659-662.

    • Search Google Scholar
    • Export Citation
  • 145

    BrinkerBTWallerEKLeongT. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer2006;106:2171-2180.

    • Search Google Scholar
    • Export Citation
  • 146

    AttalMHarousseauJLeyvrazS. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood2006;108:3289-3294.

    • Search Google Scholar
    • Export Citation
  • 147

    SpencerAPrinceMRobertsA. First analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) trial of thalidomide and alternate day prednisolone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLG MM6) [abstract]. Blood2006;108:Abstract 58.

    • Search Google Scholar
    • Export Citation
  • 148

    MorganGJDaviesFECavenaghJDJacksonGH. Position statement on the use of bortezomib in multiple myeloma. Int J Lab Hematol2008;30:1-10.

  • 149

    BarlogieBTricotGAnaissieE. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med2006;354:1021-1030.

  • 150

    McCarthyPLOwzarKStadtmauerEA. Phase III intergroup study of lenalidomide (CC-5013) versus placebo maintenance therapy following single autologous stem cell transplant for multiple myeloma (CALGB 100104): initial report of patient accrual and adverse events [abstract]. Blood2009;114:Abstract 3416.

    • Search Google Scholar
    • Export Citation
  • 151

    McCarthyPLOwzarKAndersonKC. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]. Haematologica2011;96(s1):S23.

    • Search Google Scholar
    • Export Citation
  • 152

    AttalMOliverPLauwersVC. Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial [abstract]. Haematologica2011;96(s1):S23.

    • Search Google Scholar
    • Export Citation
  • 153

    KneppersEvan der HoltBKerstenMJ. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Bloodin press.

    • Search Google Scholar
    • Export Citation
  • 154

    BrowmanGPBergsagelDSicheriD. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1995;13:2354-2360.

    • Search Google Scholar
    • Export Citation
  • 155

    FritzELudwigH. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol2000;11:1427-1436.

    • Search Google Scholar
    • Export Citation
  • 156

    ShustikCBelchARobinsonS. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol2007;136:203-211.

    • Search Google Scholar
    • Export Citation
  • 157

    RichardsonPSonneveldPSchusterM. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood2007;110:3557-3560.

    • Search Google Scholar
    • Export Citation
  • 158

    JagannathSRichardsonPGSonneveldP. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia2007;21:151-157.

    • Search Google Scholar
    • Export Citation
  • 159

    MoreauPPylypenkoHGrosickiS. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol2011;12:431-440.

    • Search Google Scholar
    • Export Citation
  • 160

    OrlowskiRNaglerASonneveldP. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol2007;25:3892-3901.

    • Search Google Scholar
    • Export Citation
  • 161

    MikhaelJRBelchARPrinceHM. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol2009;144:169-175.

    • Search Google Scholar
    • Export Citation
  • 162

    JagannathSBarlogieBBerensonJ. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol2004;127:165-172.

    • Search Google Scholar
    • Export Citation
  • 163

    JagannathSRichardsonPGBarlogieB. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica2006;91:929-934.

    • Search Google Scholar
    • Export Citation
  • 164

    DimopoulosMSpencerAAttalM. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med2007;357:2123-2132.

    • Search Google Scholar
    • Export Citation
  • 165

    WeberDMChenCNiesvizkyR. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med2007;357:2133-2142.

    • Search Google Scholar
    • Export Citation
  • 166

    RichardsonPJagannathSHusseinM. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; prelininary results [abstract]. Blood2005;106:Abstract 1565.

    • Search Google Scholar
    • Export Citation
  • 167

    RichardsonPGWellerEJagannathS. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol2009;27:5713-5719.

    • Search Google Scholar
    • Export Citation
  • 168

    AndersonKCJagannathSJakubowiakA. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study [abstract]. J Clin Oncol2009;27:Abstract 8536.

    • Search Google Scholar
    • Export Citation
  • 169

    RichardsonPGJagannathSJakubowiakAJ. Phase II Trial of lenalidomide, bortezomib, and dexamethasone in patients (pts) with relapsed and relapsed/refractory multiple myeloma (MM): updated efficacy and safety data after >2 years of follow-up [abstract]. Blood2010;116:Abstract 3049.

    • Search Google Scholar
    • Export Citation
  • 170

    MorganGJScheySAWuP. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol2007;137:268-269.

    • Search Google Scholar
    • Export Citation
  • 171

    DaviesFEWuPJennerM. The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone. Haematologica2007;92:1149--1150.

    • Search Google Scholar
    • Export Citation
  • 172

    KropffMBispingGSchuckE. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol2007;138:330-337.

    • Search Google Scholar
    • Export Citation
  • 173

    PalumboAGiacconeLBertolaA. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica2001;86:399-403.

    • Search Google Scholar
    • Export Citation
  • 174

    AnagnostopoulosAWeberDRankinK. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol2003;121:768-771.

  • 175

    PalumboABertolaAFalcoP. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J2004;5:318-324.

    • Search Google Scholar
    • Export Citation
  • 176

    AlexanianRWeberDAnagnostopoulosA. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol2003;40:3-7.

    • Search Google Scholar
    • Export Citation
  • 177

    LeeCBarlogieBMunshiN. DT-PACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol2003;21:2732-2739.

    • Search Google Scholar
    • Export Citation
  • 178

    RajkumarSVFonsecaRDispenzieriA. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc2000;75:897-901.

  • 179

    MohtyMAttalMMaritG. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant2005;35:165-169.

    • Search Google Scholar
    • Export Citation
  • 180

    SinghalSMehtaJDesikanR. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med1999;341:1565-1571.

  • 181

    WaageAGimsingPJuliussonG. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematol2004;125:149-155.

    • Search Google Scholar
    • Export Citation
  • 182

    KropffMBaylonHGHillengassJ. Optimum dose of thalidomide for relapsed multiple myeloma [abstract]. Blood2009;114:Abstract 959.

  • 183

    KnopSStrakaCHaenM. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica2005;90:1287-1288.

    • Search Google Scholar
    • Export Citation
  • 184

    MichaelMBrunsIBolkeE. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res2010;15:13-19.

  • 185

    LenhardREJr.OkenMMBarnesJM. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer1984;53:1456-1460.

    • Search Google Scholar
    • Export Citation
  • 186

    LazzarinoMCorsoABarbaranoL. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant2001;28:835-839.

    • Search Google Scholar
    • Export Citation
  • 187

    DadacaridouMPapanicolaouXMaltesasD. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON2007;12:41-44.

    • Search Google Scholar
    • Export Citation
  • 188

    BerensonJRLichtensteinAPorterL. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol1998;16:593-602.

    • Search Google Scholar
    • Export Citation
  • 189

    BerensonJRLichtensteinAPorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med1996;334:488-493.

    • Search Google Scholar
    • Export Citation
  • 190

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558-567.

    • Search Google Scholar
    • Export Citation
  • 191

    ZervasKVerrouETeleioudisZ. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006;134:620-623.

    • Search Google Scholar
    • Export Citation
  • 192

    MorganGJDaviesFEGregoryWM. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet2010;376:1989-1999.

    • Search Google Scholar
    • Export Citation
  • 193

    BoydKMorganGDaviesF. Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results [abstract]. J Clin Oncol2011;29:Abstract 8010.

    • Search Google Scholar
    • Export Citation
  • 194

    MorganGJDaviesFGregoryW. Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival (OS) benefit associated with treatment with zoledronic acid (ZOL) [abstract]. J Clin Oncol2011;29:Abstract 8083.

    • Search Google Scholar
    • Export Citation
  • 195

    MajorPPColemanRE. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program. Semin Oncol2001;28:17-24.

    • Search Google Scholar
    • Export Citation
  • 196

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558-567.

    • Search Google Scholar
    • Export Citation
  • 197

    PecherstorferMSteinhauerEURizzoliR. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer2003;11:539-547.

    • Search Google Scholar
    • Export Citation
  • 198

    LindsleyHTellerDNoonanB. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med1973;54:682-688.

    • Search Google Scholar
    • Export Citation
  • 199

    LudwigHFritzEKotzmannH. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med1990;322:1693-1699.

  • 200

    OsterborgABoogaertsMACiminoR. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma—a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Blood1996;87:2675-2682.

    • Search Google Scholar
    • Export Citation
  • 201

    IkhlaqueNSeshadriVKathulaSBaumannM. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol2006;81:420-422.

    • Search Google Scholar
    • Export Citation
  • 202

    BazRLiLKottke-MarchantK. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc2005;80:1568-1574.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 602 602 23
PDF Downloads 370 370 7
EPUB Downloads 0 0 0